-
EP3455259
European procedure
Extract from the Register of European Patents
EP About this file: EP3455259
| EP3455259 - COMBINATION OF ANTI-PD-1 ANTIBODIES AND RADIATION TO TREAT CANCER [Right-click to bookmark this link] | Status | No opposition filed within time limit Status updated on 05.01.2024 Database last updated on 03.09.2024 | |
| Former | The patent has been granted Status updated on 27.01.2023 | ||
| Former | Grant of patent is intended Status updated on 14.09.2022 | ||
| Former | Examination is in progress Status updated on 11.02.2020 | ||
| Former | Request for examination was made Status updated on 15.02.2019 | ||
| Former | The international publication has been made Status updated on 17.11.2017 | ||
| Former | unknown Status updated on 15.06.2017 | Most recent event Tooltip | 05.01.2024 | No opposition filed within time limit | published on 07.02.2024 [2024/06] | Applicant(s) | For all designated states Regeneron Pharmaceuticals, Inc. 777 Old Saw Mill River Road Tarrytown, NY 10591 / US | [2019/12] | Inventor(s) | 01 /
SKOKOS, Dimitris c/o Regeneron Pharmaceuticals Inc. 777 Old Saw Mill River Road Tarrytown, NY 10591 / US | 02 /
LOWY, Israel c/o Regeneron Pharmaceuticals Inc. 777 Old Saw Mill River Road Tarrytown, NY 10591 / US | [2019/12] | Representative(s) | J A Kemp LLP 80 Turnmill Street London EC1M 5QU / GB | [2023/09] |
| Former [2019/12] | J A Kemp 14 South Square Gray's Inn London WC1R 5JJ / GB | Application number, filing date | 17727767.0 | 12.05.2017 | [2019/12] | WO2017US32397 | Priority number, date | US201662335743P | 13.05.2016 Original published format: US 201662335743 P | US201662340142P | 23.05.2016 Original published format: US 201662340142 P | US201662348546P | 10.06.2016 Original published format: US 201662348546 P | US201662350305P | 15.06.2016 Original published format: US 201662350305 P | US201662364920P | 21.07.2016 Original published format: US 201662364920 P | US201662374020P | 12.08.2016 Original published format: US 201662374020 P | US201762451274P | 27.01.2017 Original published format: US 201762451274 P | [2019/12] | Filing language | EN | Procedural language | EN | Publication | Type: | A1 Application with search report | No.: | WO2017197259 | Date: | 16.11.2017 | Language: | EN | [2017/46] | Type: | A1 Application with search report | No.: | EP3455259 | Date: | 20.03.2019 | Language: | EN | The application published by WIPO in one of the EPO official languages on 16.11.2017 takes the place of the publication of the European patent application. | [2019/12] | Type: | B1 Patent specification | No.: | EP3455259 | Date: | 01.03.2023 | Language: | EN | [2023/09] | Search report(s) | International search report - published on: | EP | 16.11.2017 | Classification | IPC: | C07K16/28, A61N5/00, A61N5/10 | [2019/12] | CPC: |
A61K39/39541 (EP,IL,US);
C07K16/18 (IL,US);
C07K16/2818 (EP,CN,IL,KR,US);
A61N5/103 (CN);
A61K39/395 (IL,US);
A61K39/39558 (CN,IL,US);
A61K39/39575 (IL,US);
A61K45/06 (CN);
A61K47/6849 (EP,IL,US);
A61K51/1045 (IL,US);
A61N5/06 (IL,US);
A61N5/0603 (IL,US);
A61P35/00 (EP,CN,IL,KR,US);
A61P35/04 (EP,CN,IL,US);
C07K16/28 (IL,US);
C07K16/2803 (IL,US);
C07K16/2878 (EP,IL,US);
C07K16/3053 (IL,US);
A61K2039/505 (EP,CN,IL,KR,US);
A61K2039/507 (EP,CN,IL,US);
A61K2039/545 (EP,CN,IL,KR,US);
A61K2300/00 (IL,US);
A61N2005/0604 (IL,US);
A61N2005/0605 (IL,US);
A61N2005/0606 (IL,US);
A61N2005/0607 (IL,US);
A61N2005/0608 (IL,US);
A61N2005/0609 (IL,US);
A61N2005/061 (IL,US);
A61N2005/0611 (IL,US);
A61N2005/1098 (EP,IL,US);
C07K2317/21 (EP,IL,KR,US);
C07K2317/51 (CN);
C07K2317/515 (CN);
C07K2317/565 (CN);
C07K2317/73 (IL,KR,US);
C07K2317/76 (EP,IL,KR,US)
(-)
| C-Set: |
A61K39/39541, A61K2300/00 (EP,US);
A61K39/39558, A61K2300/00 (CN) | Designated contracting states | AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR [2019/12] | Extension states | BA | Not yet paid | ME | Not yet paid | Validation states | MA | 13.11.2018 | MD | 13.11.2018 | Title | German: | KOMBINATION VON ANTI-PD-1-ANTIKÖRPERN UND STRAHLUNG ZUR BEHANDLUNG VON KREBS | [2019/12] | English: | COMBINATION OF ANTI-PD-1 ANTIBODIES AND RADIATION TO TREAT CANCER | [2019/12] | French: | COMBINAISON D'ANTICORPS ANTI-PD-1 ET DE RAYONNEMENT POUR TRAITER LE CANCER | [2019/12] | Entry into regional phase | 13.11.2018 | National basic fee paid | 13.11.2018 | Designation fee(s) paid | 13.11.2018 | Examination fee paid | Examination procedure | 13.11.2018 | Amendment by applicant (claims and/or description) | 13.11.2018 | Examination requested [2019/12] | 13.11.2018 | Date on which the examining division has become responsible | 14.02.2020 | Despatch of a communication from the examining division (Time limit: M06) | 15.09.2020 | Despatch of communication that the application is deemed to be withdrawn, reason: reply to the communication from the examining division not received in time | 17.11.2020 | Reply to a communication from the examining division | 17.02.2021 | Despatch of a communication from the examining division (Time limit: M06) | 13.08.2021 | Reply to a communication from the examining division | 15.09.2022 | Communication of intention to grant the patent | 20.01.2023 | Fee for grant paid | 20.01.2023 | Fee for publishing/printing paid | 20.01.2023 | Receipt of the translation of the claim(s) | Opposition(s) | 04.12.2023 | No opposition filed within time limit [2024/06] | Request for further processing for: | The application is deemed to be withdrawn due to failure to reply to the examination report | 17.11.2020 | Request for further processing filed | 17.11.2020 | Full payment received (date of receipt of payment) Request granted | 24.11.2020 | Decision despatched | Fees paid | Renewal fee | 21.05.2019 | Renewal fee patent year 03 | 17.03.2020 | Renewal fee patent year 04 | 19.05.2021 | Renewal fee patent year 05 | 18.05.2022 | Renewal fee patent year 06 |
| Opt-out from the exclusive Tooltip competence of the Unified Patent Court | See the Register of the Unified Patent Court for opt-out data | ||
| Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court. | Lapses during opposition Tooltip | EE | 01.03.2023 | LT | 01.03.2023 | LV | 01.03.2023 | SM | 01.03.2023 | [2023/48] |
| Former [2023/46] | LT | 01.03.2023 | |
| LV | 01.03.2023 | ||
| SM | 01.03.2023 | ||
| Former [2023/36] | LT | 01.03.2023 | |
| LV | 01.03.2023 | ||
| Former [2023/33] | LT | 01.03.2023 | Cited in | International search | [XI]WO2015112800 (REGENERON PHARMA [US]); | by applicant | US6808710 | US7087411 | US7488802 | US7812135 | US8008449 | US8168757 | US8354509 | US8591886 | US8609089 | US8686119 | US8709424 | US8779105 | US8900587 | US2015203579 | US2015203580 | US2015368349 | US2015366174 | US9228016 | WO2016124558 | US2016305947 | WO2016191751 |